Pursuant to section 23(4A) of the Medicines Act 1981, the Minister of Health hereby renews the provisional consent to the sale, supply or use in New Zealand of the medicine set out in the Schedule hereto:
Schedule
Product: Xigris
Active Ingredient: Drotrecogin alfa (activated) 20mg
Dosage Form: Powder for infusion
New Zealand Sponsor: Eli Lilly and Company (NZ) Limited
Manufacturer: DSM Pharmaceuticals Inc, Greenville, North Carolina, United States of America
Note: This renewed consent is valid for two years from 19 September 2008.
Product: Xigris
Active Ingredient: Drotrecogin alfa (activated) 5mg
Dosage Form: Powder for infusion
New Zealand Sponsor: Eli Lilly and Company (NZ) Limited
Manufacturer: DSM Pharmaceuticals Inc, Greenville, North Carolina, United States of America
Note: This renewed consent is valid for two years from 19 September 2008.
Dated this 4th day of September 2008.
ANTHONY HILL, Deputy Director-General, Sector Accountability and Funding Directorate (pursuant to delegation given by the Minister of Health on 6 July 2001).